Overview

VEL-101 to Prevent Rejection After Kidney Transplantation

Status:
NOT_YET_RECRUITING
Trial end date:
2028-10-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of VEL-101 compared with tacrolimus in patients undergoing kidney transplantation.
Phase:
PHASE2
Details
Lead Sponsor:
Veloxis Pharmaceuticals
Treatments:
Tacrolimus